发明名称 Dimethylarginine dimethylaminohydrolase inhibitors and methods of use thereof
摘要 The present disclosure provides DDAH modulators. Thus, the present disclosure provides a method of treating a patient suffering from a disorder characterized by excessive NO production and/or elevated DDAH activity, the method comprising administering to said patient an effective amount of a compound of one of formulae I-X. The present disclosure also provides a pharmaceutical composition comprising a compound of one of formulae I-X.
申请公布号 US9011882(B2) 申请公布日期 2015.04.21
申请号 US201313766336 申请日期 2013.02.13
申请人 The Board of Trustees of the Leland Stanford Junior University 发明人 Ghebremariam Yohannes T.;Cooke John P.
分类号 A61K9/00;A61K31/542;A61K31/4439;A61K31/437;A61K31/428;A61M11/04;A61M15/00;A61M16/14;A61K31/444 主分类号 A61K9/00
代理机构 Bozicevic, Field & Francis, LLP 代理人 Bozicevic, Field & Francis, LLP ;Borden Paula A.
主权项 1. A method of treating an individual suffering from idiopathic pulmonary fibrosis, the method comprising administering to the individual an effective amount of a pharmaceutical formulation comprising: a) a dimethylarginine dimethylaminohydrolase (DDAH) inhibitor of one of the following formulas: wherein Q1 is N or CH; R1 is selected from alkyl, substituted alkyl, hydroxy, alkoxy, substituted alkoxy, amino, substituted amino, carboxyl, carboxyl ester, cyano, halogen, acyl, aminoacyl, nitro, alkenyl, substituted alkenyl, alkynyl, and substituted alkynyl; R2, R3, R4, and R5 are independently selected from hydrogen, alkyl, substituted alkyl, hydroxy, alkoxy, substituted alkoxy, amino, substituted amino, carboxyl, carboxyl ester, cyano, halogen, acyl, aminoacyl, nitro, alkenyl, substituted alkenyl, alkynyl, and substituted alkynyl; and m is an integer from zero to four; wherein R1 is selected from alkyl, substituted alkyl, hydroxy, alkoxy, substituted alkoxy, amino, substituted amino, carboxyl, carboxyl ester, cyano, halogen, acyl, aminoacyl, nitro, alkenyl, substituted alkenyl, alkynyl, and substituted alkynyl; R2, R3, R4, and R5 are independently selected from is selected from alkyl, substituted alkyl, hydroxy, alkoxy, substituted alkoxy, amino, substituted amino, carboxyl, carboxyl ester, cyano, halogen, acyl, aminoacyl, nitro, alkenyl, substituted alkenyl, alkynyl, and substituted alkynyl; and m is an integer from zero to four; wherein R1 is selected from alkyl, substituted alkyl, hydroxy, alkoxy, substituted alkoxy, amino, substituted amino, carboxyl, carboxyl ester, cyano, halogen, acyl, aminoacyl, nitro, alkenyl, substituted alkenyl, alkynyl, and substituted alkynyl; R2, R3, R4, and R5 are independently selected from is selected from alkyl, substituted alkyl, hydroxy, alkoxy, substituted alkoxy, amino, substituted amino, carboxyl, carboxyl ester, cyano, halogen, acyl, aminoacyl, nitro, alkenyl, substituted alkenyl, alkynyl, and substituted alkynyl; and m is an integer from zero to four; and b) a flowable formulation suitable for delivery by inhalation, wherein said pharmaceutical formulation is administered locally to the airways wherein the DDAH inhibitor is administered in a dosage range of from about 1 μg to 10 mg.
地址 Palo Alto CA US